Improving the Identification and Management of Fibrosing Interstitial Lung Diseases Through the Power of the Multidisciplinary Care Team

This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada

Program Description

Fibrosing interstitial lung diseases (F-ILDs) encompasses progressive lung conditions including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which are characterized by irreversible lung scarring, chronic cough, and high mortality rates. Currently, antifibrotic therapies are the primary strategy for treating ILDs, but these therapies are limited by their ability to slow disease progression rather than reverse existing lung scarring as well as high rates of adverse effects (AEs), particularly gastrointestinal and skin-related issues that contribute to suboptimal medication use and high discontinuation rates. Newer generation therapies offer potential improvements in both tolerability and novel mechanisms of action. As these new classes of medications move towards approval, pharmacists must understand their unique mechanisms of action to prepare for new monotherapy and combination therapy paradigms. This program will review the latest clinical evidence for the rapidly evolving F-ILD treatment landscape, preparing specialty pharmacists to integrate new therapies into existing workflows. Patient-centered cases emphasizing the value of the multidisciplinary care team will be presented to address the complexities of real-world treatment and management decisions for patients living with F-ILDs.

Target audience: Specialty pharmacists
Type of Activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate the pathophysiology and clinical burden of fibrosing interstitial lung diseases (F-ILDs) and idiopathic pulmonary fibrosis from progressive pulmonary fibrosis through updated diagnostic guidelines and recommended testing methods
• Examine currently approved antifibrotic therapies for F-ILD and their mechanisms of action, with attention to data on emerging therapeutic agents in the F-ILD pipeline and their potential impact on clinical care
• Provide activities and actions to use when working with the multidisciplinary team and the patient with an F-ILD by leveraging their consultation skills, sharing education with patients and their caregivers about their disease, and improving access to treatments that respect developments in clinical research, treatment guidelines, and emerging therapies.